Elanco Animal Health Incorporated

Elanco Animal Health Incorporated

ELANยทNYSE

$24.58

+3.9%
HealthcareDrug Manufacturers - Specialty & Generic

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

At a Glance

Live Snapshot
Market Cap$12.28B
EPS-0.4700
P/E Ratio-52.30
Earnings Date08/06/2026
3Y-14.0%
5Y-25.0%
10Y+65.0%
3Y-17.0%
5Y-26.0%
10Y+535.0%
3Y-10.0%
5Y-23.0%
10Y-7.0%
elan

Elanco Animal Health Incorporated Funding & Solvency Profile

ELAN ยท NYSE
Cash & Cash Equivalents545.00M
Net Receivables940.00M
Inventory1.74B
Other Current Assets236.00M
Total Current Assets3 B
Property, Plant & Equipment1.41B
Goodwill & Intangible Assets8.19B
Long-Term Investments0.00
Other Non-Current Assets304.00M
Total Non-Current Assets2 B
Total Assets
13.36B

Financial Health Analysis

Current Ratio

2.17x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.04x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

2 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

26% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Elanco Animal Health Incorporated Balance Sheet

ELAN โ€ข NYSE

Elanco Animal Health Incorporated Balance SheetDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
ASSETS
CURRENT ASSETS
545M
468M
352M
345M
638M
495M
334M
474.8M
323.4M
258.8M
545M
468M
352M
345M
638M
495M
334M
474.8M
323.4M
258.8M
940M
886M
1B
1B
1B
1.1B
889.9M
709.4M
601.9M
630.7M
940M
805M
842M
797M
833M
872M
816.9M
651.8M
567.4M
585M
0.0
81M
168M
205M
195M
205M
73M
57.6M
34.5M
45.7M
1.7B
1.6B
1.7B
1.5B
1.4B
1.6B
1.1B
1B
1.1B
875.6M
0.0
0.0
0.0
0.0
237M
256M
87.4M
113.9M
136.1M
182.3M
236M
287M
310M
394M
0.0
11M
11.1M
202.7M
0.0
0.0
3.5B
3.2B
3.4B
3.3B
3.3B
3.4B
2.4B
2.5B
2.1B
1.9B
NON-CURRENT ASSETS
1.4B
993M
1B
999M
1.1B
1.3B
955.3M
922.4M
920.3M
741.8M
4.8B
4.4B
5.1B
6B
6.2B
6.2B
3B
3B
3B
2.6B
3.4B
3.7B
4.5B
4.8B
5.6B
6.4B
2.5B
2.5B
2.7B
2.6B
8.2B
8.1B
9.6B
10.8B
11.8B
12.6B
5.5B
5.4B
5.6B
5.2B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
15.3M
12.3M
9M
304M
311M
341M
378M
390M
348M
185M
103.1M
242M
204M
9.9B
9.4B
11B
12.2B
13.2B
14.3B
6.6B
6.5B
6.8B
6.2B
13.4B
12.6B
14.4B
15.5B
16.5B
17.7B
9B
9B
8.9B
8.1B
LIABILITIES
CURRENT LIABILITIES
368M
296M
270M
390M
416M
501M
239M
205.2M
208.6M
228.2M
368M
296M
270M
390M
416M
501M
222.6M
205.2M
203.8M
228.2M
0.0
0.0
0.0
0.0
0.0
0.0
16.4M
0.0
4.8M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
254.8M
83.2M
74M
44M
38M
388M
294M
555M
24.5M
29M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
4.8M
7.5M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
367.6M
0.0
0.0
1.2B
975M
933M
924M
937M
1B
555M
736.5M
169.2M
307.5M
1.6B
1.3B
1.2B
1.7B
1.6B
2.1B
818.5M
970.7M
632.6M
618.9M
NON-CURRENT LIABILITIES
3.9B
4.3B
5.7B
5.4B
6B
5.6B
2.3B
2.4B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
109.1M
0.0
0.0
0.0
449M
567M
662M
765M
900M
100.8M
114.6M
251.9M
227.5M
1.3B
477M
595M
390M
533M
668M
189.1M
230.6M
265M
225.4M
5.2B
5.2B
6.9B
6.5B
7.3B
7.1B
2.6B
2.8B
516.9M
452.9M
6.8B
6.5B
8.1B
8.2B
9B
9.2B
3.4B
3.8B
1.1B
1.1B
SHAREHOLDERS' EQUITY
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
8B
7.5B
0.0
8.8B
8.8B
8.7B
8.7B
8.7B
5.6B
5.4B
0.0
0.0
-2.2B
-2B
-2.3B
-1.1B
-979M
-477M
84.3M
16.4M
0.0
0.0
-141M
-771M
-266M
-392M
-209M
303M
-173.7M
-222.2M
-256.6M
-456.9M
8.9B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
10.5M
0.0
6.5B
6.1B
6.2B
7.3B
7.5B
8.5B
5.5B
5.2B
7.8B
7B
6.5B
6.1B
6.2B
7.3B
7.5B
8.5B
5.5B
5.2B
7.8B
7B
SUMMARY
13.4B
12.6B
14.4B
15.5B
16.5B
17.7B
9B
9B
8.9B
8.1B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
15.3M
12.3M
9M
4B
4.3B
5.8B
5.8B
6.3B
6.1B
2.4B
2.5B
0.0
0.0
3.5B
3.9B
5.4B
5.5B
5.7B
5.6B
2B
2B
-323.4M
-258.8M
496,863,473
496,863,473
496,863,473
496,863,473
496,863,473
496,863,473
496,863,473
496,863,473
496,863,473
496,863,473

SEC Filings

ELAN - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 27, 2026
May 21, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 08, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

February 24, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 24, 2026
February 24, 2026
2026
8-K

8-K 2026

N/A

January 12, 2026
January 12, 2026
2026
8-K

8-K 2025

N/A

December 09, 2025
December 05, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 05, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

November 05, 2025
November 05, 2025
2025
Showing 1 to 10 of 164 filings